标准化粉尘螨滴剂治疗单一和多重过敏变应性鼻炎患儿的长期疗效评估

发布时间：2018-04-28 23:29

本文选题：鼻炎 + 变应性　；参考：《临床耳鼻咽喉头颈外科杂志》2015年12期

【摘要】：目的:评估标准化粉尘螨滴剂舌下特异性免疫治疗(SLIT)对单一过敏和多重过敏变应性鼻炎(AR)患儿的长期疗效。方法:根据皮肤点刺试验结果将162例接受标准化粉尘螨滴剂SLIT治疗的AR患儿分为单一过敏组和多重过敏组。在治疗前、治疗2年和停药3年评估两组患儿的鼻部症状总评分(TNSS)、药物总评分(TMS)和不良反应发生率。结果:SLIT治疗2年、停药3年后,单一过敏组的TNSS(分别为3.14[2.47;3.65]、3.45[2.76;3.92])和TMS(分别为0.42[0.36;0.57]、0.35[0.26;0.44])均显著低于治疗前(TNSS为9.00[8.00;10.00],TMS为2.16[1.88;2.37]),差异有统计学意义(均P0.05);SLIT治疗2年、停药3年后,多重过敏组的TNSS(分别为3.14[2.46;3.63]、4.23[3.65;4.96])和TMS(分别为0.42[0.36;0.58]、0.50[0.34;0.72])均显著低于治疗前(TNSS为9.00[8.00;10.00],TMS为2.18[1.95;2.37]),差异有统计学意义(均P0.05)。SLIT治疗前、治疗2年,单一过敏组与多重过敏组TNSS、TMS分别进行组间比较,差异均无统计学意义(均P0.05);停药3年后,单一过敏组TNSS、TMS均低于多重过敏组,差异有统计学意义(均P0.05)。治疗期间仅有11例(单一过敏组7例,多重过敏组4例)患儿发生轻微不良反应,并且两组之间的不良反应发生率差异无统计学意义(P0.05)。结论:标准化粉尘螨滴剂对单一和多重过敏的AR患儿均有长期疗效。此外,对于多重过敏患儿,尚需更长的SLIT疗程(2年)来巩固疗效。
[Abstract]:Objective: to evaluate the long-term efficacy of sublingual specific immunotherapy with standardized Dermatophagoides farinae drop in children with single or multiple allergic rhinitis. Methods: according to the results of skin prick test, 162 children with AR received SLIT were divided into single allergic group and multiple allergic group. Before treatment, 2 years after treatment and 3 years after withdrawal, the total score of nasal symptom (TNSS), total score of medicine (MS) and the incidence of adverse reactions were evaluated in both groups. Results TNSS (3.14 [2.470.65] 3.45 [2.763.92]) and TMS3200.35 (0.42 [0.360.57] 0.35 [0.260.44]) in single allergic group were significantly lower than those before treatment (9.00 [8.00 卤10.00] TMS 2.16 [1.88 卤2.37]) after treatment. TNSS (3.14 [2.46 卤3.63] 4.23 [3.654.96]) and P0.05).SLIT (0.42 [0.360.58] 0.50 [0.340.72]) in multiple allergy group were significantly lower than those before treatment (9.00 [8.00 ~ 10.00] P0.05).SLIT 2.18 [1.952.37]). There was no significant difference between the two groups (P 0.05), and the TNSS TMS in the single allergy group was lower than that in the multiple allergy group after 3 years (all P 0.05). There were only 11 children with mild adverse reactions (7 in single allergy group and 4 in multiple allergy group), and there was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion: standardized Dermatophagoides farinae drops have long-term efficacy in children with single or multiple allergic AR. In addition, for children with multiple allergies, a longer SLIT course (2 years) is needed to consolidate the efficacy.
【作者单位】：武汉市儿童医院耳鼻咽喉科;
【基金】：湖北省自然科学基金(No:2008CDZ059) 武汉市卫生局基金(No:WX09A06)
【分类号】：R765.21

【参考文献】